


The BII Bio Studio Program

Cardiometabolic Diseases



The Bio Studio program supports world-leading entrepreneurial Principal Investigators (PIs) who want to translate their innovative research ideas into new solutions to the benefit of planetary and human health.

What do we offer?

Located in Copenhagen, Denmark, BII offers office and laboratory facilities, business development support, access to mentoring and international networks, plus unique funding opportunities.

How do we unleash your project's commercial potential?

The PI will remain at their host institution, and each Bio Studio project will establish a team at BII in Copenhagen led by an Entrepreneur in Residence. Bio Studio projects will be supported by a tailored program to develop entrepreneurial and commercial competencies of the team and by dedicated BII anchors to help guide project progression.

What are the key outcomes?

The goal of each project is to create a viable startup that can raise seed or Series A financing.

How is the project funded and what is the duration?

Projects are expected to run for up to **3 years** and the funding is awarded in sequential 1-year in-kind grants of **up to EUR 1M per year** pending on annual approval of extension based on the milestone plan.




Do I need existing IP to apply? What happens if there is existing IP for the project?

There is no requirement to have existing IP to apply for Bio Studio. Any existing IP relating to the project (background IP), must be licensable to the future spin-out company on market terms. Any IP generated during Bio Studio remains the property of the host institution, but must also be licensable to the spin-out company. BII's IP specialist can assist in devising and advising on IP strategy while in the Bio Studio program.

Cardiometabolic Diseases (CMD) Open Call

Deadline for 'Expression of Interest' Submissions: 6th May 2024

BII's Bio Studio program is looking for projects based on science or technology with platform potential for developing novel therapeutic solutions for cardiometabolic diseases. Specifically, projects aiming to treat obesity, cardiovascular diseases (CVD) or diabetes as detailed below:

-  Obesity treatments that increase energy expenditure and/or preserve lean muscle mass while creating quality weight loss
-  All CVDs are of interest, including atherosclerosis, atrial fibrillation, cardiomyopathies, heart failure, heart attack, and overall risk reduction for CVD
-  Early intervention strategies to prevent type 2 diabetes or novel diabetes therapies that either preserve and prolong Beta-cell viability or increase insulin sensitivity

BII is keen to fund innovative platform technologies that can scale to identify multiple new treatment targets or new ways to target known targets within the CMD area. Projects that are focused on developing a single asset, where there is no potential for developing multiple assets in the future, are not of interest.

Want to know more?

Our guidelines contain detailed information on the application process. Scan the QR code to visit www.bii.dk/bio-studio/ to check your eligibility criteria and find more information about our Open Calls for Bio Studio.

BII BioInnovation
Institute



Questions?

Do you have questions regarding the Bio Studio program, or are you interested in feedback on your 'Expression of Interest' before applying?

Contact

Åshild Vågene
Associate, Science Strategy
avg@bii.dk